Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is an amido thiophene derivative classified as a small molecule. It acts as an inhibitor of the Hepatitis C Virus (HCV) RNA polymerase, specifically targeting the viral enzyme responsible for RNA synthesis. Its primary mechanism is inhibition of EC 2.7.7.6 (RNA-directed RNA polymerase), which is essential for HCV replication. The drug has been studied experimentally but has not reached clinical approval or advanced clinical development stages[1][3][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 3-[isopropyl(4-methylbenzoyl)amino]-5-phenylthiophene-2-carboxylic acid.